Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Advanced Proteome Therapeutics Corporation V.APC.H

Alternate Symbol(s):  APTCF

Healthcare Biotechnology
Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.


TSXV:APC.H - Post by User

Advanced Proteome Therapeutics Corporation
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Trader8on Apr 09, 2018 12:16pm
16 Views
Post# 27853308

RE:RE:The good part of the news release is here!

RE:RE:The good part of the news release is here!
sailor1986 wrote:
Wonnetr wrote: "The BCUSA showcases biotechs with advanced therapeutics and brings them together with pharma partnering executives and institutional investors, bankers and advisers. The programme featured panels on pharma-biotech dealmaking, advances in different therapeutics areas and a keynote and roundtable on investment."


All we need is excellent animal tests results than sky is a limit.

.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities